JP2014504362A - Ｌｒｒｋ２のためのアッセイ及びバイオマーカー - Google Patents

Ｌｒｒｋ２のためのアッセイ及びバイオマーカー Download PDF

Info

Publication number
JP2014504362A
JP2014504362A JP2013542113A JP2013542113A JP2014504362A JP 2014504362 A JP2014504362 A JP 2014504362A JP 2013542113 A JP2013542113 A JP 2013542113A JP 2013542113 A JP2013542113 A JP 2013542113A JP 2014504362 A JP2014504362 A JP 2014504362A
Authority
JP
Japan
Prior art keywords
alkyl
methyl
formula
certain embodiments
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013542113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504362A5 (es
Inventor
デイジー ブストス，
ドナルド カークパトリック，
トレイシー クラインハインツ，
ジョン モファット，
ツォーチュアン ション，
シュオ チャン，
ハイタオ チュー，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2014504362A publication Critical patent/JP2014504362A/ja
Publication of JP2014504362A5 publication Critical patent/JP2014504362A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2013542113A 2010-11-30 2011-11-29 Ｌｒｒｋ２のためのアッセイ及びバイオマーカー Pending JP2014504362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41820810P 2010-11-30 2010-11-30
US61/418,208 2010-11-30
PCT/US2011/062468 WO2012075046A1 (en) 2010-11-30 2011-11-29 Assays and biomarkers for lrrk2

Publications (2)

Publication Number Publication Date
JP2014504362A true JP2014504362A (ja) 2014-02-20
JP2014504362A5 JP2014504362A5 (es) 2015-01-15

Family

ID=45217723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542113A Pending JP2014504362A (ja) 2010-11-30 2011-11-29 Ｌｒｒｋ２のためのアッセイ及びバイオマーカー

Country Status (9)

Country Link
EP (1) EP2646819A1 (es)
JP (1) JP2014504362A (es)
KR (1) KR20130121903A (es)
CN (1) CN103348243A (es)
BR (1) BR112013013457A2 (es)
CA (1) CA2818428A1 (es)
MX (1) MX2013005801A (es)
RU (1) RU2013129818A (es)
WO (1) WO2012075046A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3902A (en) 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
US9582909B2 (en) * 2012-11-15 2017-02-28 Shimadzu Corporation Chromatograph mass spectrometry data processing device
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN105331721A (zh) * 2015-11-27 2016-02-17 首都医科大学宣武医院 检测pd致病基因突变的方法，及其引物、试剂盒
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
MX2020004666A (es) 2017-11-17 2022-01-26 Cellix Bio Private Ltd Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122789A2 (en) * 2007-04-05 2008-10-16 Medical Research Council Methods for modulating lrrk2
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007261095A1 (en) 2006-06-20 2007-12-27 Novartis Ag Biomarkers for the progression of Alzheimer's disease
WO2008091799A2 (en) * 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US8367349B2 (en) * 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122789A2 (en) * 2007-04-05 2008-10-16 Medical Research Council Methods for modulating lrrk2
JP2010523101A (ja) * 2007-04-05 2010-07-15 メディカル リサーチ カウンセル Ｌｒｒｋ２の調整方法
US20100175140A1 (en) * 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015041266; Ｇｌｏｅｃｋｎｅｒ　ＣＪ　ｅｔ　ａｌ．: 'Ｐｈｏｓｐｈｏｐｅｐｔｉｄｅ　ａｎａｌｙｓｉｓ　ｒｅｖｅａｌｓ　ｔｗｏ　ｄｉｓｃｒｅｔｅ　ｃｌｕｓｔｅｒｓ　ｏｆ　ｐｈｏｓｐｈｏｒｙｌａｔｉｏｎ　ｉｎ　ｔｈｅ　Ｎ-ｔｅｒｍｉｎｕｓ　ａｎｄ　ｔｈｅ　Ｒ' Ｊ　Ｐｒｏｔｅｏｍｅ　Ｒｅｓ ９（４）, 20100405, １７３８-１７４５ *
JPN6015041267; Ｐｏｏｊａ　Ｐ．　Ｐｕｎｇａｌｉｙａ　ｅｔ　ａｌ．: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ　ａｎｄ　Ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ａ　Ｌｅｕｃｉｎｅ-Ｒｉｃｈ　Ｒｅｐｅａｔ　Ｋｉｎａｓｅ　２　（ＬＲＲＫ２）　Ｃｏｎｓｅｎｓｕｓ　Ｐｈｏｓｐｈｏｒｙｌａｔ' ＰＬＯＳ　ＯＮＥ Ｖｏｌ．　５，　Ｉｓｓｕｅ　１０, 20101027 *

Also Published As

Publication number Publication date
CN103348243A (zh) 2013-10-09
MX2013005801A (es) 2013-07-17
WO2012075046A9 (en) 2012-09-13
BR112013013457A2 (pt) 2017-07-11
KR20130121903A (ko) 2013-11-06
CA2818428A1 (en) 2012-06-07
WO2012075046A1 (en) 2012-06-07
RU2013129818A (ru) 2015-01-10
EP2646819A1 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
JP2014504362A (ja) Ｌｒｒｋ２のためのアッセイ及びバイオマーカー
Leonard et al. Selective PP2A enhancement through biased heterotrimer stabilization
McPhie et al. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3
Xu et al. Modulating TRADD to restore cellular homeostasis and inhibit apoptosis
Hague et al. Selective inhibition of α1A-adrenergic receptor signaling by RGS2 association with the receptor third intracellular loop
Chou et al. GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress
Shilling et al. Lack of evidence for presenilins as endoplasmic reticulum Ca2+ leak channels
Burchell et al. The Parkinson's disease–linked proteins Fbxo7 and Parkin interact to mediate mitophagy
Sheng et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations
Lince-Faria et al. Spatiotemporal control of mitosis by the conserved spindle matrix protein Megator
Tang et al. Netrin-1 mediates neuronal survival through PIKE-L interaction with the dependence receptor UNC5B
Yoon et al. Homer1 promotes dendritic spine growth through ankyrin-G and its loss reshapes the synaptic proteome
Carrel et al. NOS1AP regulates dendrite patterning of hippocampal neurons through a carboxypeptidase E-mediated pathway
K Bhosle et al. Nuclear localization of platelet-activating factor receptor controls retinal neovascularization
Bentley et al. Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis
Janel et al. Plasma DYRK1A as a novel risk factor for Alzheimer’s disease
Tan et al. Dissociation of mitochondrial HK-II elicits mitophagy and confers cardioprotection against ischemia
Kaplan et al. Linking cytoplasmic dynein and transport of Rab8 vesicles to the midbody during cytokinesis by the doublecortin domain-containing 5 protein
P Kelly Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?
Tao et al. Golgi-resident TRIO regulates membrane trafficking during neurite outgrowth
KR20090048192A (ko) 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
Suomi et al. Autophagy in the mammalian nervous system: a primer for neuroscientists
Meredith et al. P-glycoprotein efflux and other factors limit brain amyloid β reduction by β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice
Thomas et al. Bin1 antibody lowers the expression of phosphorylated tau in Alzheimer's disease
Yoon et al. cAMP Signaling–Mediated Phosphorylation of Diacylglycerol Lipase α Regulates Interaction With Ankyrin-G and Dendritic Spine Morphology

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160614